Regulatory Replimune gets early August decision date for twice-rejected melanoma drug BioSpaceReplimune's resubmission for RP1 for melanoma comes after the departures of FDA leaders in place at the time of the drug's first two rejections.OncologyRead full story pharminent June 26, 2026 (Last updated: June 26, 2026) BioSpace Replimune’s resubmission for RP1 for melanoma comes after the departures of FDA leaders in place at the time of the drug’s first two rejections. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Moderna looks out to R&D ‘horizons’ as 2028 break-even goal loomsNext: Moderna Maps R&D ‘Horizons’ as 2028 Break-Even Goal Looms Related Stories Regulatory Celcuity gets FDA nod for first-in-class breast cancer drug pharminent July 15, 2026 Regulatory FDA clears at-home start dose for Alzheimer’s drug Leqembi pharminent July 14, 2026 Regulatory FDA posts new rejection letters days after confirming pause pharminent July 13, 2026
